CABRELLIS PHARMACEUTICALS
Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.
CABRELLIS PHARMACEUTICALS
Industry:
Health Care Health Diagnostics Pharmaceutical Therapeutics
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Total Employee:
11+
Status:
Active
Contact:
(858)404-1777
Total Funding:
27.5 M USD
Similar Organizations
Conforma Therapeutics
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer.
Novita Pharmaceuticals
Novita Pharmaceuticals is a developer of therapeutic drugs for the treatment of cancer.
Therinject
Therinject is a pharmaceutical company focused on developing therapeutics for the treatment of cancer.
Investors List
Novo Holdings
Novo Holdings investment in Series A - Cabrellis Pharmaceuticals
Lilly Ventures
Lilly Ventures investment in Series A - Cabrellis Pharmaceuticals
RiverVest
RiverVest investment in Series A - Cabrellis Pharmaceuticals
Domain Associates
Domain Associates investment in Series A - Cabrellis Pharmaceuticals
RBC Venture Partners
RBC Venture Partners investment in Series A - Cabrellis Pharmaceuticals
Forward Ventures
Forward Ventures investment in Series A - Cabrellis Pharmaceuticals
SR One
SR One investment in Series A - Cabrellis Pharmaceuticals
ProQuest Investments
ProQuest Investments investment in Series A - Cabrellis Pharmaceuticals
More informations about "Cabrellis Pharmaceuticals"
Cabrellis Pharmaceuticals - Funding, Financials, Valuation
Cabrellis Pharmaceuticals is funded by 8 investors. Novo Holdings and Lilly Ventures are the most recent investors. Which investors participated in the most funding rounds?See details»
Cabrellis Pharmaceuticals - PitchBook
How much funding has Cabrellis Pharmaceuticals raised over time? Cabrellis Pharmaceuticals has raised $27.5M. Who are Cabrellis Pharmaceuticals’s investors? Domain Associates, …See details»
Press Release: Pharmion Acquires Cabrellis Pharmaceuticals
Nov 16, 2006 Dainippon Sumitomo Pharmaceuticals, the original developer of amrubicin, licensed the Japanese marketing rights to Nippon Kayaku in January 2005, and the North …See details»
Pharmion Acquires Cabrellis Pharmaceuticals
Nov 16, 2006 Dainippon Sumitomo Pharmaceuticals, the original developer of amrubicin, licensed the Japanese marketing rights to Nippon Kayaku in January 2005, and the North …See details»
Cabrellis Pharmaceuticals Corporation Company Profile | Summit, …
Find company research, competitor information, contact details & financial data for Cabrellis Pharmaceuticals Corporation of Summit, NJ. Get the latest business insights from Dun & …See details»
Cabrellis Pharmaceuticals - Ownership and Business Overview
Cabrellis Pharmaceuticals was founded in 2006. Life Science M&A Summary in 2006 Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2006 .See details»
Cabrellis Pharmaceuticals Corp. - Drug pipelines, Patents, Clinical ...
Explore Cabrellis Pharmaceuticals Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news.See details»
Cabrellis Pharmaceuticals - Crunchbase
Cabrellis Pharmaceuticals Corporation develops therapies for the treatment of cancer.See details»
Cabrellis Pharmaceuticals Corporation - Rivervest
10996 Torreyana Road, Suite 280 San Diego, CA 92121. Phone: (314) 726.6700See details»
Cabrellis Pharmaceuticals Corp - Company Profile and News
Company profile page for Cabrellis Pharmaceuticals Corp including stock price, company news, executives, board members, and contact informationSee details»
Cabrellis Pharmaceuticals Corporation - VentureRadar
Cabrellis Pharmaceuticals Corporation VentureRadar profile. Find out more about Cabrellis Pharmaceuticals Corporation including the VentureRadar Innovation and Growth scores, …See details»
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights To …
Dec 4, 2006 Pharmion Corporation announced that it has acquired Cabrellis Pharmaceuticals, a clinical-stage private oncology company dedicated to the development of amrubicin, a third …See details»
CABRELLIS PHARMACEUTICALS CORPORATION - SAN DIEGO, CA
CABRELLIS PHARMACEUTICALS CORPORATION C. CABRELLIS PHARMACEUTICALS CORPORATION CLAIM THIS BUSINESS. 9393 TOWNE CENTRE DR SAN DIEGO, CA …See details»
Cabrellis Pharmaceuticals Corporation - Products, Competitors ...
Cabrellis Pharmaceuticals Corporation was a Healthcare/Pharmaceuticals / Drugs company based in San Diego, California. Use the CB Insights Platform to explore Cabrellis …See details»
Cabrellis Pharmaceuticals - Products, Competitors, Financials ...
Use the CB Insights Platform to explore Cabrellis Pharmaceuticals's full profile. Cabrellis Pharmaceuticals - Products, Competitors, Financials, Employees, Headquarters Locations …See details»
Pharmion nets cancer therapy in Cabrellis buyout
Nov 15, 2006 Pharmion has acquired a mid-stage lung cancer therapy--amrubicin--in its deal to buy Cabrellis Pharmaceuticals for $59 million up front. Cabrellis shareholders will also get …See details»
Cabrellis Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks
Cabrellis Pharmaceuticals Corporation develops therapies for the treatment of cancer. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Pharmion Purchases Cabrellis, US Developer of Amrubicin
Dec 1, 2006 Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II …See details»
Pharmion Acquires Cabrellis: $59M For Lung Cancer Drug
Nov 17, 2006 The amrubicin license became the main focus of specialty pharma firm Cabrellis, carved out of the Biogen arrangement. (See BioWorld Today, May 4, 2006.) "I was selling the …See details»
Torrent Pharmaceutical gets CDSCO Panel nod to conduct …
11 hours ago New Delhi: Responding to the proposal presented by Torrent Pharmaceutical to manufacture and market Prucalopride oral solution 0.2 mg/ml, the Subject Expert Committee …See details»